Update in chronic obstructive pulmonary disease: Role of antioxidant and metabolizing gene polymorphisms

Experimental Lung Research

Volumn 37, Issue 6, 2011, Pages 364-375

  Lakhdar, Ramzi ^a   Denden, Sabri ^a   Kassab, Asma ^b   Leban, Nadia ^a   Knani, Jalel ^c   Lefranc, Gérard ^c   Miled, Abelhadi ^b   Chibani, Jemni Ben ^a   Khelil, Amel Haj ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b FARHAT HACHED HOSPITAL   (Tunisia)

^c INSTITUTE OF HUMAN GENETICS   (France)

Author keywords

Antioxidant genes; COPD; Genetic polymorphism; Oxidative stress; Xenobiotic enzymes

Indexed keywords

ANTIOXIDANT; CATALASE; CYTOCHROME P450; EPOXIDE HYDROLASE; FREE RADICAL; GLUTATHIONE TRANSFERASE; HEME OXYGENASE 1; SUPEROXIDE DISMUTASE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DNA POLYMORPHISM; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANTIOXIDANTS; HUMANS; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REACTIVE OXYGEN SPECIES; SMOKING;

EID: 79960713682     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2011.580416     Document Type: Review

References (131)

1. World Health Organization (WHO): 2011. Chronic Respi ratory Diseases. Available at http://www.who.int/respiratory/ copd/burden/en/index.html. Accessed February 1, 2011.
2. Sethi JM, Rochester CL: Smoking and chronic obstructive pulmonary disease. Clin Chest Med. 2000;21:67-86. (Pubitemid 30183773)
3. Zaher C, Halbert R, Dubois R, et al.: Smoking related diseases: the importance of COPD. Int J Tuberc Lung Dis. 2004;8:1423-1428. (Pubitemid 40070247)
4. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD): Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. Executive Summary updated 2009. Available at: http://www. goldcopd.com/Guidelineitem.asp?l1=2&l2=1&int Id=989. Accessed February 1, 2011.
5. Chung KF, Marwick JA: Molecular mechanisms of oxida-tive stress in airways and lungs with reference to asthma and chronic obstructive pulmonary disease. Ann N Y Acad Sci. 2010;1203:85-91.
6. Wanner A, Mendes ES: Airway endothelial dysfunction in asthma and chronic obstructive pulmonary disease: a challenge for future research. Am J Respir Crit Care Med. 2010;182:1344-1351.
7. Huertas A, Palange P: Circulating endothelial progenitor cells and chronic pulmonary diseases. Eur Respir J. 2011;37:426-431.
8. Barnes PJ: Mechanisms and resistance in glucocorticoid control of infammation. J Steroid Biochem Mol Biol. 2010;120:76-85.
9. Barnes PJ, Shapiro SD, Pauwels RA: Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22:672-688. (Pubitemid 37258549)
10. Mac Nee W: Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:258-266. (Pubitemid 41566933)
11. O'Donnell R, Breen D, Wilson S, Djukanovic R. Infammatory cells in the airways in COPD. Thorax 2006; 61: 448-454.
12. Stockley RA: Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med. 1999;160:S49-S52.
13. Tuder RM, Yoshida T, Arap W, et al.: State of the art. Cellular and molecular mechanisms of alveolar destruction in emphysema: an evolutionary perspective. Proc Am Thorac Soc. 2006;3:503-510. (Pubitemid 44285536)
14. Demedts IK, Demoor T, Bracke KR, et al.: Role of apopto-sis in the pathogenesis of COPD and pulmonary emphysema. Respir Res. 2006;7:53.
15. Mac Nee W: Oxidants/antioxidants and COPD. Chest. 2000;117:303S-317S. (Pubitemid 30327005)
16. Mac Nee W: Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:50-60. (Pubitemid 40562963)
17. Rahman I, Skwarska E, Henry M, et al.: Systemic and pulmonary oxidative stress in idiopathic pulmonary fbrosis. Free Radic Biol Med. 1999;27:60-68. (Pubitemid 29353084)
18. Mac Nee W, Rahman I: Is oxidative stress central to the patho-genesis of chronic obstructive pulmonary disease? Trends Mol Med. 2001;7:55-62. (Pubitemid 33718642)
19. Burrows B, Knudson RJ, Cline MG, Lebowitz MD: Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis. 1977;115:195-205. (Pubitemid 8036155)
20. Fletcher C, Peto R, Tinker C, Speizer FE: Factors related to the development of airfow obstruction. In: The Natural History of Chronic Bronchitis and Emphysema. Oxford, UK: Oxford University Press; 1976:70-105.
21. Redline S, Tishler PV, Rosner B, et al.: Genotypic and pheno-typic similarities in pulmonary function among family members of adult monozygotic and dizygotic twins. Am J Epidemiol. 1989;129:827-836. (Pubitemid 19094260)
22. Lewitter FI, Tager IB, McGue M, et al.: Genetic and environmental determinants of level of pulmonary function. Am J Epidemiol. 1984;120:518-529.
23. Kueppers F, Miller RD, Gordon H, et al.: Familial prevalence of chronic obstructive pulmonary disease in a matched pair study. Am J Med. 1977;63:336-342. (Pubitemid 8190924)
24. Cohen BH: Chronic obstructive pulmonary disease: a challenge in genetic epidemiology. Am J Epidemiol. 1980;112: 274-288. (Pubitemid 10018966)
25. Hallberg J, Iliadou A, Anderson M, et al.: Genetic and environmental infuence on lung function impairment in Swedish twins. Respir Res. 2010;11:92.
26. Seifart C, Plagens A: Genetics of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2007;2: 541-550.
27. Black LF, Kueppers F: α1 antitrypsin defciency in nonsmok-ers. Am Rev Respir Dis. 1978;17:421-428.
28. Rajendrasozhan S, Yang SR, Edirisinghe I, et al.: Deacety-lases and NF-kappa B in redox regulation of cigarette smoke-induced lung infammation: epigenetics in pathogenesis of COPD. Antioxid Redox Signal. 2008;10:799-811. (Pubitemid 351225898)
29. Park HS, Kim SR, Lee YC: Impact of oxidative stress on lung diseases. Respirology. 2009;14:27-38.
30. Pryor WA, Stone K: Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci. 1993;686:12-27.
31. Rahman I, Mac Nee W: Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radic Biol Med. 1996;21:669-681. (Pubitemid 26331096)
32. Reiter RJ: Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J. 1995;9:526-533.
33. Lee W, Thomas PS: Oxidative stress in COPD and its measurement through exhaled breath condensate. Clin Transl Sci. 2009;2:150-155.
34. Ceylan E, Kocyigit A, Gencer M, et al.: Increased DNA damage in patients with chronic obstructive pulmonary disease who had once smoked or been exposed to biomass. Respir Med. 2006;100:1270-1276. (Pubitemid 43793057)
35. Kanazawa H, Yoshikawa J: Elevated oxidative stress and reciprocal reduction of vascular endothelial growth factor levels with severity of COPD. Chest. 2005;128:3191-3197. (Pubitemid 41698640)
36. Cavalcante AG, de Bruin PF: The role of oxidative stress in COPD: current concepts and perspectives. J Bras Pneumol. 2009;35:1227-1237.
37. Wang DG, Fan JB, Siao CJ, et al.: Large-scale identif-cation, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science. 1998;280:1077-1082. (Pubitemid 28234949)
38. Strachan T, Read AP: Human Molecular Genetics. Oxford, UK: Garland Science Publishers; 2003.
39. The International Hap Map Consortium: A Haplotype Map of the Human Genome. Nature. 2005;437:1299-1320.
40. Hap Map. Web site. Available at: http://www.hapmap.org./ Last accessed 1 February 2011.
41. Punturieri A, Szabo E, Croxton TL, et al.: Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst. 2009;101: 554-559.
42. Barnes PJ: Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med. 2010;7:e1000220.
43. Spira A, Beane J, Shah V, et al.: Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci U S A. 2004;101:10143-10148. (Pubitemid 38891209)
44. Spira A, Beane JE, Shah V, et al.: Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med. 2007;13:361-366. (Pubitemid 46376687)
45. Pierrou S, Broberg P, O'Donnell RA, et al.: Expression of genes involved in oxidative stress responses in airway epithelial cells of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:577-586. (Pubitemid 46438942)
46. Silverman EK, Spira A, Paré PD: Genetics and genomics of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6:539-542.
47. Wang X, Chorley BN, Pittman GS, et al.: Genetic variation and antioxidant response gene expression in the bronchial airway epithelium of smokers at risk for lung cancer. PLoS One. 2010;5:e11934.
48. Maines MD: Heme oxygenase: function, multiplicity, regulatory mechanisms and clinical application. FASEB J. 1988;2:2557-2568.
49. Tenhunen R, Marver HS, Schmid R: Microsomal heme oxygenase: characterization of the enzyme. J Biol Chem. 1969;244:6388-6394.
50. Yamada N, Yamaya M, Okinaga S, et al.: Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet. 2000;66:187-195 (Pubitemid 30481482)
51. erratum Am J Hum Genet. 2001;68:1542.
52. Kimpara T, Takeda A, Watanabe K, et al.: Microsatellite polymorphism in the human heme oxygenase-1 gene promoter and its application in association studies with Alzheimer and Parkinson disease. Hum Genet. 1997;100:145-147. (Pubitemid 27309669)
53. Ono K, Mannami T, Iwai N: Association of a promoter variant of the haem oxygenase-1 gene with hypertension in women. J Hypertens. 2003;21:1497-1503. (Pubitemid 36994128)
54. Ono K, Goto Y, Takagi S, et al.: A promoter variant of the heme oxygenase-1 gene may reduce the incidence of ischemic heart disease in Japanese. Atherosclerosis. 2004;173:313-317.
55. Guénégou A, Leynaert B, Bénessiano J, et al.: Association of lung function decline with the heme oxygenase-1 gene promoter microsatellite polymorphism in a general population sample. Results from the European Community Respiratory Health Survey (ECRHS), France. J Med Genet. 2006;43:e43.
56. He JQ, Ruan J, Connett JE, et al.: Antioxidant gene polymorphisms and susceptibility to rapid decline in lung function in smokers. Am J Respir Crit Care Med. 2002;166:323-328. (Pubitemid 34864420)
57. Forsberg L, de Faire U, Morgenstern R: Oxidative stress, human genetic variation, and disease. Arch Biochem Biophys. 2001;389:84-93. (Pubitemid 32911546)
58. Wang LI, Miller DP, Sai Y, et al.: Manganese superoxide dis-mutase alanine-to-valine polymorphism at codon 16 and lung cancer. J Natl Cancer Int. 2001;93:1818-1821. (Pubitemid 33150455)
59. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, et al.: Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to infu-ence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochem Biophys Res Commun. 1996;226:561-565. (Pubitemid 26331940)
60. Olsen DA, Petersen SV, Oury TD, et al.: The intracellular processing of extracellular dismutase (EC-SOD) is a two step event. J Biol Chem. 2004;279:22152-22157. (Pubitemid 38679408)
61. Young RP, Hopkins R, Black PN, et al.: Functional variants of antioxidant genes in smokers with COPD and in those with normal lung function. Thorax. 2006;61:394-399. (Pubitemid 43723321)
62. Arcaroli JJ, Hokanson JE, Abraham E, et al.: Extracellular superoxide dismutase haplotypes are associated with acute lung injury and mortality. Am J Respir Crit Care Med. 2009;179:105-112.
63. Mak JC, Ho SP, Yu WC, et al.: Polymorphisms and functional activity in superoxide dismutase and catalase genes in smokers with COPD. Eur Respir J. 2007;30:684-690. (Pubitemid 351194828)
64. Dahl M, Bowler RP, Juul K, et al.: Superoxide dismu-tase 3 polymorphism associated with reduced lung function in two large populations. Am J Respir Crit Care Med. 2008;178:906-912.
65. Ganguly K, Depner M, Fattman C, et al.: Superoxide dismu-tase 3, extracellular (SOD3) variants and lung function. Phys-iol Genomics. 2009;37:260-267.
66. Castaldi PJ, Cho MH, Cohn M, et al.: The COPD genetic association compendium: a comprehensive online database of COPD genetic associations. Hum Mol Genet. 2010;19:526-534.
67. Sørheim IC, De Meo DL, Washko G, et al.: International COPD Genetics Network Investigators. Polymorphisms in the superoxide dismutase-3 gene are associated with emphysema in COPD. COPD. 2010;7:262-268.
68. Quan F, Korneluk RG, Tropak MB, Gravel RA: Isolation and characterization of the human catalase gene. Nucleic Acids Res. 1986;14:5321-5335. (Pubitemid 16092775)
69. Forsberg L, Lyrenas L, de Faire U, Morgenstern R: Acommon functional C-T substitution polymorphism in the promoter region of the human catalase gene infuences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. Free Radic Biol Med. 2001;30:500-505. (Pubitemid 32162956)
70. Nebert DW, Vasiliou V: Analysis of the glutathione S trans-ferase (GST) gene family. Hum. Genomics. 2004;1:460-464.
71. Pemble S, Schroeder KR, Spencer SR, et al.: Human glu-tathione S-transferase theta (GSTT1): c DNA cloning and the characterization of a genetic polymorphism. Biochem J. 1994;300:271-276. (Pubitemid 24151046)
72. Board PG, Webb GC, Coggan M: Isolation of a c DNA clone and localization of the human glutathione S-transferase 3 genes to chromosome bands 11q13 and 12q13-14. Ann Hum Genet. 1989;53:205-213. (Pubitemid 19201747)
73. Johansson AS, Stenberg G, Widersten M, Mannervik B: Structure activity relationships and thermal stability of human glu-tathione transferase P1-1 governed by the H-site residue 105. J Mol Biol. 1998;278:687-698. (Pubitemid 28224864)
74. Eaton DL, Bammler TK: Concise review of the glutathione S-transferase and their signifcance to toxicology. Toxicol Sci. 1999;49:156-164. (Pubitemid 29300401)
75. Harrison DJ, Cantlay AM, Rae F, et al.: Frequency of glu-tathione S transferase M1 deletion in smokers with emphysema and lung cancer. Hum Exp Toxicol. 1997;16:356-360. (Pubitemid 27371243)
76. Cantlay AM, Smith CAD, Wallace WA, et al.: Heterogeneous expression and polymorphic genotype of glutathione S-transferase in human lung. Thorax. 1994;49:1010-1014. (Pubitemid 24315995)
77. Baranova H, Perriot J, Albuisson E, et al.: Peculiarities of the GSTM1 0/0 genotype in French heavy smokers with various types of chronic bronchitis. Hum Genet. 1997;99:822-826. (Pubitemid 27243765)
78. Ishii T, Matsuse T, Teramoto S, et al.: Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. Thorax. 1999;54: 693-696. (Pubitemid 29341405)
79. Yim JJ, Park GY, Lee CT, et al.: Genetic susceptibility to chronic obstructive pulmonary disease in Koreans: combined analysis of polymorphic genotypes for microsomal epoxide hy-drolase and glutathione S-transferase M1 and T1. Thorax. 2000;55:121-125. (Pubitemid 30245951)
80. Lu B, He Q: Correlation between exon 5 polymorphism of glutathione S-transferase P1 gene and susceptibility to chronic obstructive pulmonary disease in northern Chinese population of Han nationality living in Beijing. Zhonghua Nei Ke Za Zhi. 2002;41:678-681.
81. Cheng SL, Yu CJ, Chen CJ, Yang PC: Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD. Eur Respir J. 2004;23:818-824.
82. Xiao D, Wang C, Du MJ, Christiani DC: Relationship between polymorphisms of genes encoding microsomal epoxide hydro-lase and glutathione S-transferase P1 and chronic obstructive pulmonary disease. Chin Med J. 2004;117:661-667. (Pubitemid 38735820)
83. Hersh CP, Demeo DL, Lange C, et al.: Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol. 2005;33:71-78. (Pubitemid 40961016)
84. Zidzik J, Slabá E, Joppa P, et al.: Glutathione S-transferase and microsomal epoxide hydrolase gene polymorphisms and risk of chronic obstructive pulmonary disease in Slovak population. Croat Med J. 2008;49:182-191. (Pubitemid 351669458)
85. Lakhdar R, Denden S, Knani J, et al.: Association between GST M1 and GSTT1 polymorphisms with COPD in Tunisian population. Biochem Genet. 2010;48:647-657.
86. Mehrotra S, Sharma A, Kumar S, et al. Polymorphism of glu-tathione S-transferase M1 and T1 gene loci in COPD. Int J Immunogenet. 2010;37:263-267.
87. Faramawy MM, Mohammed TO, Hossaini AM, et al. Genetic polymorphism of GSTT1 and GSTM1 and susceptibility to chronic obstructive pulmonary disease (COPD). J Crit Care. 2009;24:e7-e10.
88. Thakur H, Gupta L, Sobti RC, et al.: Association of GSTM1T1 genes with COPD and prostate cancer in north Indian population. Mol Biol Rep. 2011;38:1733-1739.
89. Imboden M, Downs SH, Senn O, et al.: Glutathione S-transferase genotypes modify lung function decline in the general population: SAPALDIA cohort study. Respir Res. 2007;11:8:2.
90. Harries LW, Stubbins MJ, Forman D, et al.: Identification of genetic polymorphisms at the glutathione S-transferase P1 locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis. 1997;18:641-644. (Pubitemid 28132446)
91. Rodríguez F, de la Roza C, Jardi R, et al.: Glutathione S-transferase P1 and lung function in patients with α1-antitrypsin defciency and COPD. Chest. 2005;127: 1537-1543. (Pubitemid 46218777)
92. Lakhdar R, Denden S, Knani J, et al.: Relationship between glutathione S-transferase P1 polymorphisms and chronic obstructive pulmonary disease in Tunisian population. Genet Mol Res. 2010;9:897-907.
93. Zimniak P, Nandur B, Pikula S, et al.: Naturally occurring human glutathione S-transferase GSTP-1 isoforms with isoleucine and valine in position 104 differ in enzymatic properties. Eur J Biochem. 1994;224:893-899. (Pubitemid 24288851)
94. Watson MA, Stewart RK, Smith GB, et al.: Human glu-tathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis. 1998;19:275-280. (Pubitemid 28375421)
95. Sundberg K, Johansson AS, Stenberg G, et al.: Differences in the catalytic effciencies of allelic variants of glutathione trans-ferase P1 towards carcinogenesis diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis. 1998;19:433-436. (Pubitemid 28375445)
96. Hu X, O'Donnell R, Srivastava SK, et al.: Active site architecture of polymorphic forms of human glutathione S-transferase P1 accounts for their enantioselectivity and sisparate activity in the glutathione conjugation of 7B, 8alpha-dihydroxy-9alpha:10alpha-oxy-7, 8, 9, 10-tetrahydrobenzeno(a)pyrene. Biochem Biophys Res Commun. 1997;235:424-428. (Pubitemid 27313724)
97. Yan F, Chen C, Jing J, et al. Association between polymorphism of glutathione S-transferase P1 and chronic obstructive pulmonary disease: a meta-analysis. Respir Med. 2010;104:473-480.
98. Smolonska J, Wijmenga C, Postma DS, Boezen HM: Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years' research. Am J Respir Crit Care Med. 2009;180:618-631.
99. Curtis JO, Hassett C, Hosagrahara V: Epoxide hydrolase-polymorphism and role in toxicology. Toxicol Lett. 2000;112-113:365-370.
100. Seidegard J, Ekstrom G: The role of human glutathione trans-ferases and epoxide hydrolases in the metabolism of xenobi-otics. Environ Health Perspect. 1997;105:791-799. (Pubitemid 27372964)
101. Hassett C, Aicher L, Sidhu JS, et al.: Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet. 1994;3:421-428. (Pubitemid 24083901)
102. Smith CA, Harrison DJ: Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet. 1997;350:630-633. (Pubitemid 27367797)
103. Yoshikawa M, Hiyama K, Ishioka S, et al.: Microsomal epoxide hydrolase genotypes and chronic obstructive pulmonary disease in Japanese. Int J Mol Med. 2000;5:49-53.
104. Rodriguez F, Jardi R, Costa X, et al.: Detection of polymorphisms at exons 3 (Tyr113→His) and 4 (his139→Arg) of the microsomal epoxide hydrolase gene using fuorescence PCR method combined with melting curves analysis. Anal Biochem. 2002;308:120-126. (Pubitemid 35191645)
105. Park JY, Chen L, Wadhwa N, et al.: Polymorphisms for micro-somal epoxide hydrolase and genetic susceptibility to COPD. Int J Mol Med. 2005;15:443-448.
106. Budhi A, Hiyama K, Isobe T, et al.: Genetic susceptibility for emphysematous changes of the lung in Japanese. Int J Mol Med. 2003;11:321-329.
107. Takeyabu K, Yamaguchi E, Suzuk I, et al.: Gene polymorphism for microsomal epoxide hydrolase and susceptibility to emphysema in a Japanese population. Eur Respir J. 2000;15:891-894. (Pubitemid 30321846)
108. Zhang R, Zhang A, He Q, et al.: Microsomal epoxide hydrolase gene polymorphism and susceptibility to chronic obstructive pulmonary disease in Han nationality North China (in Chinese). Zhonghua Nei Ke Za Zhi. 2002;41:11-14.
109. Matheson MC, Raven J, Walters EH, et al.: Microsomal epox-ide hydrolase is not associated with COPD in a community-based sample. Hum Biol. 2006;78:705-717. (Pubitemid 47164650)
110. De Meo DL, Hersh CP, Hoffman EA, et al.: Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med. 2007;176: 42-48. (Pubitemid 47048053)
111. Chappell S, Daly L, Morgan K, et al.: Genetic variants of mi-crosomal epoxide hydrolase and glutamate-cysteine ligase in COPD. Eur Respir J. 2008;32:931-937.
112. Penyige A, Poliska S, Csanky E, et al.: Analyses of association between PPAR gamma and EPHX1 polymorphisms and susceptibility to COPD in a Hungarian cohort, a case-control study. BMC Med Genet. 2010;11:152.
113. Sandford AJ, Chagani T, Weir TD, et al.: Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med. 2001;163:469-473. (Pubitemid 32158530)
114. Lakhdar R, Denden S, Knani J, et al.: Microsomal epoxide hydrolase gene (EPHX1) polymorphisms and susceptibility to chronic obstructive pulmonary disease in Tunisian population. Genet Test Mol Biomarkers 2010;14:857-863.
115. Kim WJ, Hoffman E, Reilly J, et al.: Association of COPD candidate genes with CT emphysema and airway phenotypes in severe COPD. Eur Respir J. 2011;37:39-43.
116. Lee J, Nordestgaard BG, Dahl M: EPHX1 polymorphisms, COPD and asthma in 47, 000 individuals and in meta-analysis. Eur Respir J. 2011;37:18-25.
117. Hu G, Shi Z, Hu J, et al.: Association between polymorphisms of microsomal epoxide hydrolase and COPD: results from meta-analyses. Respirology. 2008;13:837-850.
118. Kim WJ, Hersh CP, De Meo DL, et al.: Genetic association analysis of COPD candidate genes with bronchodilator responsiveness. Respir Med. 2009;103:552-557.
119. Turesky RJ, Constable A, Richoz J, et al.: Activation of hete-rocyclic aromatic amines by rat and human liver microsomes and by purifed rat and human cytochrome p450 1A2. Chem Res Toxicol. 1998;11:925-936. (Pubitemid 28390194)
120. Landi MT, Bertazzi PA, Shields PG, et al.: Association between CYP1A1 genotype, m RNA expression and enzymatic activity in humans. Pharmacogenetics. 1994;4:242-246. (Pubitemid 24337432)
121. San Jose G, Moreno MU, Olivan S, et al.: Functional effect of the p22phox-930A/G polymorphism on p22phox expression and NADPH oxidase activity in hypertension. Hypertension. 2004;44:163-169. (Pubitemid 39014233)
122. Guzik TJ, West NEJ, Black E: Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation. 2000;102:1744-1747.
123. Minematsu N, Nakamura H, Iwata M, et al.: Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema. Thorax. 2003;58:623-628. (Pubitemid 36808135)
124. Arif E, Vibhuti A, Alam P, et al.: Association of CYP2E1 and NAT2 gene polymorphisms with chronic obstructive pulmonary disease. Clin Chim Acta. 2007;382:37-42. (Pubitemid 46782729)
125. Cheng SL, Yu CJ, Yang PC: Genetic polymorphisms of cytochrome p450 and matrix metalloproteinase in chronic obstructive pulmonary disease. Biochem Genet. 2009;47: 591-601.
126. Vibhuti A, Arif E, Mishra A, et al.: CYP1A1, CYP1A2 and CYBA gene polymorphisms associated with oxidative stress in COPD. Clin Chim Acta. 2010;411:474-480.
127. Kaur-Knudsen D, Nordestgaard BG, Tybjaerg-Hansen A, Bo-jesen SE: CYP1B1 genotype and risk of cardiovascular disease, pulmonary disease, and cancer in 50, 000 individuals. Pharma-cogenet Genomics. 2009;19:685-694.
128. Seo T, Pahwa P, McDuffe HH, et al.: Association between cytochrome P450 3A5 polymorphism and the lung function in Saskatchewan grain workers. Pharmacogenet Genomics. 2008;18:487-493. (Pubitemid 351769916)
129. Lakhdar R, Denden S, Haj Mouhamed M, et al.: Correlation of EPHX1, GSTP1, GSTM1 and GSTT1 genetic polymorphisms with anti-oxidative stress markers in COPD. Exp Lung Res. 2011;37:195-204.
130. De Meo DL, Celedon JC, Lange C, et al.: Genome-wide linkage of forced mid-expiratory fow in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:1294-301. (Pubitemid 39657193)
131. Hirschhorn JN: Genetic approaches to studying common diseases and complex traits. Pediatr Res. 2005;57:74R-77R. (Pubitemid 40593249)